Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris

William H. Frishman, Neal Klein, Joel Strom, Martin N. Cohen, Harry Shamoon, Howard Willens, Philip Klein, Steven Roth, Louis Iorio, Thierry LeJemtel, Simcha Pollack, Edmund H. Sonnenblick

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated. The comparative effects of withdrawal from long-term treatment with propranolol and verapamil were assessed in a placebo-controlled double-blind randomized crossover study of 20 patients with stable angina pectoris. Patients received placebo for 2 weeks, then increasing doses of propranolol (60 to 320 mg/day) or verapamil (240 to 480 mg/day) for 3 weeks. Patients were then abruptly withdrawn from drug onto placebo for 1 week, followed by crossover to the other drug treatment and a second withdrawal period. All 20 patients were withdrawn from verapamil without evidence of a rebound increase in frequency of anginal attacks, blood pressure, heart rate, or rate-pressure product and without a rebound deterioration in exercise tolerance. In contrast, with propranolol withdrawal, 2 patients (with the highest baseline angina attack rate) had a severe exacerbation of their anginal syndrome and could not undergo formal exercise testing; the other 18 patients were withdrawn from propranolol without Incident. Plasma catecholamlnes were increased during exercise compared with rest during all treatments; however, the levels of catecholamines during exercise were significantly higher with propranolol than with verapamil and placebo (p < 0.05). Levels of exercise catecholamines returned to placebo baseline values after withdrawal of propranolol.

Original languageEnglish (US)
Pages (from-to)1191-1195
Number of pages5
JournalThe American Journal of Cardiology
Volume50
Issue number5
DOIs
StatePublished - 1982

Fingerprint

Angina Pectoris
Verapamil
Propranolol
Placebos
Exercise
Catecholamines
Exercise Tolerance
Stable Angina
Therapeutics
Pharmaceutical Preparations
Cross-Over Studies
Heart Rate
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. / Frishman, William H.; Klein, Neal; Strom, Joel; Cohen, Martin N.; Shamoon, Harry; Willens, Howard; Klein, Philip; Roth, Steven; Iorio, Louis; LeJemtel, Thierry; Pollack, Simcha; Sonnenblick, Edmund H.

In: The American Journal of Cardiology, Vol. 50, No. 5, 1982, p. 1191-1195.

Research output: Contribution to journalArticle

Frishman, WH, Klein, N, Strom, J, Cohen, MN, Shamoon, H, Willens, H, Klein, P, Roth, S, Iorio, L, LeJemtel, T, Pollack, S & Sonnenblick, EH 1982, 'Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris', The American Journal of Cardiology, vol. 50, no. 5, pp. 1191-1195. https://doi.org/10.1016/0002-9149(82)90442-8
Frishman, William H. ; Klein, Neal ; Strom, Joel ; Cohen, Martin N. ; Shamoon, Harry ; Willens, Howard ; Klein, Philip ; Roth, Steven ; Iorio, Louis ; LeJemtel, Thierry ; Pollack, Simcha ; Sonnenblick, Edmund H. / Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. In: The American Journal of Cardiology. 1982 ; Vol. 50, No. 5. pp. 1191-1195.
@article{9af403a692fc443a85863b07a6a46bec,
title = "Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris",
abstract = "The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated. The comparative effects of withdrawal from long-term treatment with propranolol and verapamil were assessed in a placebo-controlled double-blind randomized crossover study of 20 patients with stable angina pectoris. Patients received placebo for 2 weeks, then increasing doses of propranolol (60 to 320 mg/day) or verapamil (240 to 480 mg/day) for 3 weeks. Patients were then abruptly withdrawn from drug onto placebo for 1 week, followed by crossover to the other drug treatment and a second withdrawal period. All 20 patients were withdrawn from verapamil without evidence of a rebound increase in frequency of anginal attacks, blood pressure, heart rate, or rate-pressure product and without a rebound deterioration in exercise tolerance. In contrast, with propranolol withdrawal, 2 patients (with the highest baseline angina attack rate) had a severe exacerbation of their anginal syndrome and could not undergo formal exercise testing; the other 18 patients were withdrawn from propranolol without Incident. Plasma catecholamlnes were increased during exercise compared with rest during all treatments; however, the levels of catecholamines during exercise were significantly higher with propranolol than with verapamil and placebo (p < 0.05). Levels of exercise catecholamines returned to placebo baseline values after withdrawal of propranolol.",
author = "Frishman, {William H.} and Neal Klein and Joel Strom and Cohen, {Martin N.} and Harry Shamoon and Howard Willens and Philip Klein and Steven Roth and Louis Iorio and Thierry LeJemtel and Simcha Pollack and Sonnenblick, {Edmund H.}",
year = "1982",
doi = "10.1016/0002-9149(82)90442-8",
language = "English (US)",
volume = "50",
pages = "1191--1195",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris

AU - Frishman, William H.

AU - Klein, Neal

AU - Strom, Joel

AU - Cohen, Martin N.

AU - Shamoon, Harry

AU - Willens, Howard

AU - Klein, Philip

AU - Roth, Steven

AU - Iorio, Louis

AU - LeJemtel, Thierry

AU - Pollack, Simcha

AU - Sonnenblick, Edmund H.

PY - 1982

Y1 - 1982

N2 - The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated. The comparative effects of withdrawal from long-term treatment with propranolol and verapamil were assessed in a placebo-controlled double-blind randomized crossover study of 20 patients with stable angina pectoris. Patients received placebo for 2 weeks, then increasing doses of propranolol (60 to 320 mg/day) or verapamil (240 to 480 mg/day) for 3 weeks. Patients were then abruptly withdrawn from drug onto placebo for 1 week, followed by crossover to the other drug treatment and a second withdrawal period. All 20 patients were withdrawn from verapamil without evidence of a rebound increase in frequency of anginal attacks, blood pressure, heart rate, or rate-pressure product and without a rebound deterioration in exercise tolerance. In contrast, with propranolol withdrawal, 2 patients (with the highest baseline angina attack rate) had a severe exacerbation of their anginal syndrome and could not undergo formal exercise testing; the other 18 patients were withdrawn from propranolol without Incident. Plasma catecholamlnes were increased during exercise compared with rest during all treatments; however, the levels of catecholamines during exercise were significantly higher with propranolol than with verapamil and placebo (p < 0.05). Levels of exercise catecholamines returned to placebo baseline values after withdrawal of propranolol.

AB - The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated. The comparative effects of withdrawal from long-term treatment with propranolol and verapamil were assessed in a placebo-controlled double-blind randomized crossover study of 20 patients with stable angina pectoris. Patients received placebo for 2 weeks, then increasing doses of propranolol (60 to 320 mg/day) or verapamil (240 to 480 mg/day) for 3 weeks. Patients were then abruptly withdrawn from drug onto placebo for 1 week, followed by crossover to the other drug treatment and a second withdrawal period. All 20 patients were withdrawn from verapamil without evidence of a rebound increase in frequency of anginal attacks, blood pressure, heart rate, or rate-pressure product and without a rebound deterioration in exercise tolerance. In contrast, with propranolol withdrawal, 2 patients (with the highest baseline angina attack rate) had a severe exacerbation of their anginal syndrome and could not undergo formal exercise testing; the other 18 patients were withdrawn from propranolol without Incident. Plasma catecholamlnes were increased during exercise compared with rest during all treatments; however, the levels of catecholamines during exercise were significantly higher with propranolol than with verapamil and placebo (p < 0.05). Levels of exercise catecholamines returned to placebo baseline values after withdrawal of propranolol.

UR - http://www.scopus.com/inward/record.url?scp=0020401741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020401741&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(82)90442-8

DO - 10.1016/0002-9149(82)90442-8

M3 - Article

C2 - 6814227

AN - SCOPUS:0020401741

VL - 50

SP - 1191

EP - 1195

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -